These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11334385)

  • 1. Endothelin in renal diseases and cardiovascular remodeling in renal failure.
    Orth SR; Viedt C; Amann K; Ritz E
    Intern Med; 2001 Apr; 40(4):285-91. PubMed ID: 11334385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
    Yamamoto K; Masuyama T; Sakata Y; Mano T; Nishikawa N; Kondo H; Akehi N; Kuzuya T; Miwa T; Hori M
    Cardiovasc Res; 2000 Aug; 47(2):274-83. PubMed ID: 10946064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor antagonist versus angiotensin I-converting enzyme inhibitor in experimental renal diseases.
    Jover B; Demeilliers B
    Fundam Clin Pharmacol; 2000; 14(6):541-8. PubMed ID: 11206703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases.
    Luft FC
    Curr Opin Nephrol Hypertens; 2002 Jan; 11(1):59-66. PubMed ID: 11753088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure.
    Uhlenius N; Miettinen A; Vuolteenaho O; Tikkanen I
    Kidney Blood Press Res; 2002; 25(2):71-9. PubMed ID: 12077487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence.
    Unger T; Culman J; Gohlke P
    J Hypertens Suppl; 1998 Sep; 16(7):S3-9. PubMed ID: 9855025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system.
    Yamamoto K; Masuyama T; Sakata Y; Doi R; Ono K; Mano T; Kondo H; Kuzuya T; Miwa T; Hori M
    Cardiovasc Res; 2000 Jun; 46(3):421-32. PubMed ID: 10912453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelin in cardiovascular disease.
    Agapitov AV; Haynes WG
    J Renin Angiotensin Aldosterone Syst; 2002 Mar; 3(1):1-15. PubMed ID: 11984741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ACE and AT1 inhibitors in used in the progression of chronic renal failure].
    Switalski M
    Pol Arch Med Wewn; 2002 Apr; 107(4):379-87. PubMed ID: 12189931
    [No Abstract]   [Full Text] [Related]  

  • 11. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cardiovascular changes in renal failure--ACE inhibition, endothelin receptor blockade or a combination of both strategies?
    Amann K; Münter K; Wagner J; Balajew V; Hergenröder S; Mall G; Ritz E
    Nephrol Dial Transplant; 1999; 14 Suppl 4():43-4. PubMed ID: 10463213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonists: another potential alternative for cardiovascular diseases.
    Tostes RC; Muscará MN
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):287-301. PubMed ID: 16101562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?
    Cooper ME; Webb RL; de Gasparo M
    Cardiovasc Drug Rev; 2001; 19(1):75-86. PubMed ID: 11314602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
    Campbell DJ
    Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin as a regulator of cardiovascular function in health and disease.
    Haynes WG; Webb DJ
    J Hypertens; 1998 Aug; 16(8):1081-98. PubMed ID: 9794709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.